Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


DexCom (DXCM) Falls More Steeply Than Broader Market: What Investors Need to Know

2024-04-02
In the closing of the recent trading day, DexCom (DXCM) stood at $136.65, denoting a -0.94% change from the preceding trading day.

DexCom's (NASDAQ:DXCM) investors will be pleased with their incredible 380% return over the last five years

2024-04-02
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

2024-04-02
SAN DIEGO, April 02, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4: 30 p.m. Eastern Time

2024-04-02
DexCom, Inc. today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the...

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

2024-04-01
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Micron, Dropbox And 2 Other Stocks Insiders Are Selling

2024-04-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List

2024-04-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Insider Sell: EVP Chief Legal Officer Michael Brown Sells 2,624 Shares of DexCom Inc (DXCM)

2024-03-30
DexCom Inc (NASDAQ:DXCM), a medical device company, specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes.

DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock?

2024-03-29
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

International Companies Drive Diabesity Innovation

2024-03-29
The diabetes and obesity markets are large and growing, with an estimated addressable market of $100 billion in the US alone. Read more about the companies here.